Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carcinogenic and mutagenic molecules are substances capable of causing or promoting the formation of mutations in DNA; such mutations may lead to cancer by disrupting the normal regulation of the cell cycle or fostering genetic instability[1][2][4][6][9]. These substances are commonly regulated under frameworks such as the European CLP Regulation, which categorize agents by the strength of evidence for carcinogenicity and mutagenicity[1][5][7]. Mutagens directly damage genetic material through various mechanisms (chemical adduct formation, chromosomal breaks, aneuploidy, etc.), while carcinogens may act indirectly by accelerating cell division or interfering with DNA repair, and may include physical, chemical, and biological agents (e.g., certain chemicals, radiation, human papilloma virus)[4][9].
DNA adduct formation and mutagenesis; Induction of chromosomal instability; Disruption of cell cycle regulation; Epigenetic modifications
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carcinogenic or mutagenic substance (CMR (for "Carcinogenic, Mutagenic, and Reprotoxic")).